Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

A few years ago, Emergent BioSolutions’ Bayview plant in Baltimore was known for a high-profile mishap – a batch mix-up that spoiled millions of COVID-19 vaccine doses. Today, that once-troubled facility is getting a fresh start under new ownership. Syngene International, a leading Indian contract research and manufacturing firm, is spending $36.5 million to acquire Emergent’s Baltimore Bayview biologics plant. It’s Syngene’s first manufacturing foothold in the United States, and it comes loaded with symbolism. This deal is not just a one-off for Syngene; it’s part of a larger wave of Indian biotech companies expanding into the U.S. market. And it carries implications that ripple far beyond Baltimore – from New Delhi and Washington to the global biotech supply chain.

 » Read More